Latest Content

Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions

February 14th 2025, 9:32pm

By Jason M Broderick

Article

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.

High Omega-3 Diet With Fish Oil Reduces Ki-67 Index in Prostate Cancer

February 14th 2025, 9:10pm

By Tim Cortese

Article

Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.

Neuropathy, Rash, Hyperglycemia Linked to PFS in Urothelial Carcinoma

February 14th 2025, 7:30pm

By Spencer Feldman

Article

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.

Padcev May Be Safe in Older Patients With Bladder Cancer

February 14th 2025, 6:35pm

By Darlene Dobkowski, MA

Article

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

Are We at Risk of Losing Our Breast Cancer Community?

February 14th 2025, 6:00pm

By Martha Carlson

Article

I found community after my metastatic breast cancer diagnosis, but recent discord in cancer support groups makes me fear we're losing these vital connections.

Estrogen Patches with ARPIs Found to Be Safe, Effective in Prostate Cancer

February 14th 2025, 5:15pm

By Alex Biese

Article

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.

Linvoseltamab BLA Resubmission Accepted by FDA for Review

February 14th 2025, 2:00pm

By Spencer Feldman

Article

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume

February 13th 2025, 11:49pm

By Kyle Doherty

Article

Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death by 46%, per ARANOTE data.

Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT

February 13th 2025, 10:00pm

By Alex Biese

Article

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.

An Expert Explains Updated Data For Patients With GU Cancers

February 13th 2025, 9:35pm

By Ryan Scott

Video

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.

Elevated PSA Link to Higher Recurrence Risk in Intermediate-Risk Prostate Cancer

February 13th 2025, 8:45pm

By Ryan Scott

Article

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.

Facing Cancer Together: Jim and Melanie’s Patient-Caregiver Story

February 13th 2025, 6:00pm

By Sue McCarthy

Article

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's sarcoma diagnosis.

Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma

February 13th 2025, 4:00pm

By Spencer Feldman

Article

Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma.

Talzenna Plus Xtandi May Improve Survival in mCRPC

February 13th 2025, 3:10pm

By Jordyn Sava

Article

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.

Breaking Down the Implications of Calquence Combination Therapy in MCL

February 13th 2025, 2:00pm

By Dr. Tycel Phillips

Video

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.